Retrovirus from the HIV group and its use
AssigneeDade Behring Marburg GmbH
InventorsLutz G. Guertler, Josef Eberle, Albrecht V. Brunn, Stefan Knapp, Hans-Peter Hauser
Life of this patent
Estimating the term…
Abstract
A novel immunodeficiency virus is disclosed which has the designation MVP-5180/91 and which has been deposited with the European Collection of Animal Cell Cultures (ECACC) under No. V 920 52 318. The characteristic antigens which can be obtained from it and which can be employed for detecting antibodies against retroviruses which are associated with immunodeficiency diseases are also disclosed, as are the DNA and amino acid sequences of the virus.
Claims39
1) an immunodeficiency virus of the HIV group, or variants of this virus, which exhibits the essential morphological and immunological properties of the retrovirus which has the designation MVP-5180/91 and which has been deposited with the European collection of animal cell cultures (ECACC) under no:
- V 920 92 318.
4) The immunodeficiency virus as claimed in one of the preceding claims, wherein antigen/antibody reactions with its transmembrane protein gp 41 are readily detectable using sera from patients originating from Africa, and wherein only a relatively small antigen/antibody reaction, or no such reaction, can be detected with the gp-41 using sera from patients originating from Germany.
5) The immunodeficiency virus as claimed in one of the abovementioned claims, which has an RNA sequence which is homologous to the extent of about 75% or more, based on the entire genome, with the RNA of the deposited virus.
6) The immunodeficiency virus as claimed in one of the abovementioned claims, which has an RNA sequence which is homologous to the extent of at least 75% with the RNA sequence of Table 1.
9) The immunodeficiency virus as claimed in one of the preceding claims, which has a sequence or constituent sequence which corresponds to FIG. 4 or is homologous to this sequence, where the differences from the sequence given in FIG. 4, related to the gene loci, are at most:
- LTR:
- 17%, GAG:
- 29%, POL:
- 25%, VIF:
- 31%, ENV:
- 46%, NEF:
- 16%.
10) The immunodeficiency virus as claimed in one of the preceding claims, which has a sequence or constituent sequence which corresponds to FIG. 4 or is homologous to this sequence, where the differences from the sequence given in FIG. 4, related to the gene loci, are at most:
- LTR:
- 10%, GAG:
- 14%, POL:
- 12%, VIF:
- 15%, ENV:
- 22%, NEF:
- 10%.
A nucleic acid comprising the sequence of the genome of virus MvP-5180/91 (SEQ ID NO:
- 56).
A nucleic acid comprising the sequence of SEQ ID NO:
- 38 or SEQ ID NO:
- 39.
A nucleic acid comprising the sequence of SEQ ID NO:
- 44 or SEQ ID NO:
- 45.
A nucleic acid comprising a nucleotide sequence having more than 66% homology with SEQ ID NO:
- 44 or SEQ ID NO:
- 45, over the length of SEQ ID NO:
- 44 or SEQ ID NO:
- 45, respectively.
A nucleic acid comprising a nucleotide sequence having more than 66% homology with SEQ ID NO:
- 37 or SEQ ID NO:
- 38, over the length of SEQ ID NO:
- 37 or SEQ ID NO:
- 38, respectively.
A nucleic acid comprising at least 50 consecutive nucleotides of SEQ ID NO:
- 56.
Dependencies are inferred from the claim text.